Treatment of Acute Graft-vs-Host Disease View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2009-11-27

AUTHORS

Steven C. Goldstein , Sophie D. Stein , David L. Porter

ABSTRACT

Over the last two decades, advances in our understanding of the pathophysiology of acute GVHD (aGVHD) [1, 2] have not yet translated into significant changes in upfront management. Corticosteroids have remained the cornerstone of aGVHD therapy for the last several decades, and still, failure to respond to steroids remains the primary predictor of poor overall outcome. Several issues limit the usefulness of most retrospective reports of therapeutic intervention for aGVHD. First, we must acknowledge that the majority of series using the “temporal onset” definition of acute and chronic GvHD actually included a mix of patients with either late onset acute or early chronic GvHD, confounding their interpretation and extrapolation to recent efforts to define these syndromes on the basis of clinical features regardless of timing of onset. Second is the lack of prognostic tools to identify cohorts who may need more (vs less) aggressive induction. Third, we also must acknowledge the significant variability in clinical practice between transplant physicians, often well-founded in their efforts to individualize therapy on the basis of specific organ involvement, severity of symptoms, etc. Rather than surrendering to the potentially insurmountable task of establishing a single and perhaps suboptimal standard of care for the upfront treatment of aGVHD, advances in the field and improved patient outcomes will require modern and well-designed clinical trials supported throughout the transplant community. More... »

PAGES

747-765

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_42

DOI

http://dx.doi.org/10.1007/978-1-59745-478-0_42

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043175725


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.412713.2", 
          "name": [
            "Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goldstein", 
        "givenName": "Steven C.", 
        "id": "sg:person.016115210252.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016115210252.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology-Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.412713.2", 
          "name": [
            "Department of Hematology-Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Sophie D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Allogeneic Stem Cell Transplantation, University of Pennsylvania Medical Center, Philadelphia, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.412713.2", 
          "name": [
            "Allogeneic Stem Cell Transplantation, University of Pennsylvania Medical Center, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Porter", 
        "givenName": "David L.", 
        "id": "sg:person.0707416147.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707416147.15"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009-11-27", 
    "datePublishedReg": "2009-11-27", 
    "description": "Over the last two decades, advances in our understanding of the pathophysiology of acute GVHD (aGVHD) [1, 2] have not yet translated into significant changes in upfront management. Corticosteroids have remained the cornerstone of aGVHD therapy for the last several decades, and still, failure to respond to steroids remains the primary predictor of poor overall outcome. Several issues limit the usefulness of most retrospective reports of therapeutic intervention for aGVHD. First, we must acknowledge that the majority of series using the \u201ctemporal onset\u201d definition of acute and chronic GvHD actually included a mix of patients with either late onset acute or early chronic GvHD, confounding their interpretation and extrapolation to recent efforts to define these syndromes on the basis of clinical features regardless of timing of onset. Second is the lack of prognostic tools to identify cohorts who may need more (vs less) aggressive induction. Third, we also must acknowledge the significant variability in clinical practice between transplant physicians, often well-founded in their efforts to individualize therapy on the basis of specific organ involvement, severity of symptoms, etc. Rather than surrendering to the potentially insurmountable task of establishing a single and perhaps suboptimal standard of care for the upfront treatment of aGVHD, advances in the field and improved patient outcomes will require modern and well-designed clinical trials supported throughout the transplant community.", 
    "editor": [
      {
        "familyName": "Lazarus", 
        "givenName": "Hillard M.", 
        "type": "Person"
      }, 
      {
        "familyName": "Laughlin", 
        "givenName": "Mary J.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-59745-478-0_42", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-934115-33-6", 
        "978-1-59745-478-0"
      ], 
      "name": "Allogeneic Stem Cell Transplantation", 
      "type": "Book"
    }, 
    "keywords": [
      "acute GVHD", 
      "chronic GVHD", 
      "poor overall outcome", 
      "specific organ involvement", 
      "severity of symptoms", 
      "mix of patients", 
      "upfront management", 
      "aggressive induction", 
      "acute graft", 
      "host disease", 
      "upfront treatment", 
      "timing of onset", 
      "organ involvement", 
      "clinical features", 
      "transplant physicians", 
      "patient outcomes", 
      "clinical trials", 
      "transplant community", 
      "prognostic tool", 
      "suboptimal standards", 
      "clinical practice", 
      "therapeutic intervention", 
      "late onset", 
      "GVHD", 
      "overall outcome", 
      "temporal onset", 
      "primary predictor", 
      "therapy", 
      "retrospective reports", 
      "majority of series", 
      "onset", 
      "significant changes", 
      "outcomes", 
      "treatment", 
      "corticosteroids", 
      "patients", 
      "pathophysiology", 
      "syndrome", 
      "graft", 
      "cohort", 
      "symptoms", 
      "steroids", 
      "significant variability", 
      "disease", 
      "physicians", 
      "trials", 
      "severity", 
      "care", 
      "intervention", 
      "predictors", 
      "induction", 
      "involvement", 
      "report", 
      "failure", 
      "majority", 
      "advances", 
      "cornerstone", 
      "management", 
      "lack", 
      "usefulness", 
      "timing", 
      "decades", 
      "changes", 
      "practice", 
      "insurmountable task", 
      "efforts", 
      "basis", 
      "recent efforts", 
      "standards", 
      "variability", 
      "series", 
      "features", 
      "understanding", 
      "definition", 
      "tool", 
      "community", 
      "issues", 
      "extrapolation", 
      "task", 
      "interpretation", 
      "mix", 
      "field", 
      "early chronic GvHD", 
      "more (vs less) aggressive induction"
    ], 
    "name": "Treatment of Acute Graft-vs-Host Disease", 
    "pagination": "747-765", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043175725"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-59745-478-0_42"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-59745-478-0_42", 
      "https://app.dimensions.ai/details/publication/pub.1043175725"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-12-01T20:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/chapter/chapter_441.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-59745-478-0_42"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_42'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_42'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_42'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-59745-478-0_42'


 

This table displays all metadata directly associated to this object as RDF triples.

166 TRIPLES      23 PREDICATES      109 URIs      102 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-59745-478-0_42 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N290ab9e32edd4c64bfaef9e561b18dec
4 schema:datePublished 2009-11-27
5 schema:datePublishedReg 2009-11-27
6 schema:description Over the last two decades, advances in our understanding of the pathophysiology of acute GVHD (aGVHD) [1, 2] have not yet translated into significant changes in upfront management. Corticosteroids have remained the cornerstone of aGVHD therapy for the last several decades, and still, failure to respond to steroids remains the primary predictor of poor overall outcome. Several issues limit the usefulness of most retrospective reports of therapeutic intervention for aGVHD. First, we must acknowledge that the majority of series using the “temporal onset” definition of acute and chronic GvHD actually included a mix of patients with either late onset acute or early chronic GvHD, confounding their interpretation and extrapolation to recent efforts to define these syndromes on the basis of clinical features regardless of timing of onset. Second is the lack of prognostic tools to identify cohorts who may need more (vs less) aggressive induction. Third, we also must acknowledge the significant variability in clinical practice between transplant physicians, often well-founded in their efforts to individualize therapy on the basis of specific organ involvement, severity of symptoms, etc. Rather than surrendering to the potentially insurmountable task of establishing a single and perhaps suboptimal standard of care for the upfront treatment of aGVHD, advances in the field and improved patient outcomes will require modern and well-designed clinical trials supported throughout the transplant community.
7 schema:editor N3e50cdd5e0ea46c5a8c338ef0d5be5fe
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N58e68c16d959442baebcd6c6f213ed60
12 schema:keywords GVHD
13 acute GVHD
14 acute graft
15 advances
16 aggressive induction
17 basis
18 care
19 changes
20 chronic GVHD
21 clinical features
22 clinical practice
23 clinical trials
24 cohort
25 community
26 cornerstone
27 corticosteroids
28 decades
29 definition
30 disease
31 early chronic GvHD
32 efforts
33 extrapolation
34 failure
35 features
36 field
37 graft
38 host disease
39 induction
40 insurmountable task
41 interpretation
42 intervention
43 involvement
44 issues
45 lack
46 late onset
47 majority
48 majority of series
49 management
50 mix
51 mix of patients
52 more (vs less) aggressive induction
53 onset
54 organ involvement
55 outcomes
56 overall outcome
57 pathophysiology
58 patient outcomes
59 patients
60 physicians
61 poor overall outcome
62 practice
63 predictors
64 primary predictor
65 prognostic tool
66 recent efforts
67 report
68 retrospective reports
69 series
70 severity
71 severity of symptoms
72 significant changes
73 significant variability
74 specific organ involvement
75 standards
76 steroids
77 suboptimal standards
78 symptoms
79 syndrome
80 task
81 temporal onset
82 therapeutic intervention
83 therapy
84 timing
85 timing of onset
86 tool
87 transplant community
88 transplant physicians
89 treatment
90 trials
91 understanding
92 upfront management
93 upfront treatment
94 usefulness
95 variability
96 schema:name Treatment of Acute Graft-vs-Host Disease
97 schema:pagination 747-765
98 schema:productId N55d6ee6d0f424b0d8af3241168bee0d4
99 Ne9f9992b84704cae925cfdcb2e5eb476
100 schema:publisher N441c8e7d7e914b748faa995c79f26349
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043175725
102 https://doi.org/10.1007/978-1-59745-478-0_42
103 schema:sdDatePublished 2021-12-01T20:10
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N5cc9d18e991c43b892b404b71a53b6e8
106 schema:url https://doi.org/10.1007/978-1-59745-478-0_42
107 sgo:license sg:explorer/license/
108 sgo:sdDataset chapters
109 rdf:type schema:Chapter
110 N06e69a49c1d145c8bd0e5cacf89e3fce schema:familyName Laughlin
111 schema:givenName Mary J.
112 rdf:type schema:Person
113 N290ab9e32edd4c64bfaef9e561b18dec rdf:first sg:person.016115210252.03
114 rdf:rest N800a92c377894388a17e5ca1d71d9ba4
115 N3e50cdd5e0ea46c5a8c338ef0d5be5fe rdf:first Na3f9af0cc42a4519abf34ce81fc9523f
116 rdf:rest Nc167d202d78946ab9d264e978ec54a99
117 N441c8e7d7e914b748faa995c79f26349 schema:name Springer Nature
118 rdf:type schema:Organisation
119 N55d6ee6d0f424b0d8af3241168bee0d4 schema:name dimensions_id
120 schema:value pub.1043175725
121 rdf:type schema:PropertyValue
122 N58e68c16d959442baebcd6c6f213ed60 schema:isbn 978-1-59745-478-0
123 978-1-934115-33-6
124 schema:name Allogeneic Stem Cell Transplantation
125 rdf:type schema:Book
126 N5cc9d18e991c43b892b404b71a53b6e8 schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 N6328860c3ea04f7ea6208b3646bfcdaf schema:affiliation grid-institutes:grid.412713.2
129 schema:familyName Stein
130 schema:givenName Sophie D.
131 rdf:type schema:Person
132 N800a92c377894388a17e5ca1d71d9ba4 rdf:first N6328860c3ea04f7ea6208b3646bfcdaf
133 rdf:rest Ne7f98c0410f644c3b2e5ccd2d2826981
134 Na3f9af0cc42a4519abf34ce81fc9523f schema:familyName Lazarus
135 schema:givenName Hillard M.
136 rdf:type schema:Person
137 Nc167d202d78946ab9d264e978ec54a99 rdf:first N06e69a49c1d145c8bd0e5cacf89e3fce
138 rdf:rest rdf:nil
139 Ne7f98c0410f644c3b2e5ccd2d2826981 rdf:first sg:person.0707416147.15
140 rdf:rest rdf:nil
141 Ne9f9992b84704cae925cfdcb2e5eb476 schema:name doi
142 schema:value 10.1007/978-1-59745-478-0_42
143 rdf:type schema:PropertyValue
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
148 schema:name Clinical Sciences
149 rdf:type schema:DefinedTerm
150 sg:person.016115210252.03 schema:affiliation grid-institutes:grid.412713.2
151 schema:familyName Goldstein
152 schema:givenName Steven C.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016115210252.03
154 rdf:type schema:Person
155 sg:person.0707416147.15 schema:affiliation grid-institutes:grid.412713.2
156 schema:familyName Porter
157 schema:givenName David L.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707416147.15
159 rdf:type schema:Person
160 grid-institutes:grid.412713.2 schema:alternateName Allogeneic Stem Cell Transplantation, University of Pennsylvania Medical Center, Philadelphia, PA, USA
161 Department of Hematology-Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
162 Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA
163 schema:name Allogeneic Stem Cell Transplantation, University of Pennsylvania Medical Center, Philadelphia, PA, USA
164 Department of Hematology-Oncology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
165 Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, USA
166 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...